{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T08:03:46Z","timestamp":1784189026261,"version":"3.55.0"},"reference-count":106,"publisher":"MDPI AG","issue":"14","license":[{"start":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T00:00:00Z","timestamp":1784160000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Primary liver malignancies, including hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and combined hepatocellular cholangiocarcinoma, remain major causes of cancer-related morbidity and mortality worldwide. Although systemic therapies have advanced substantially, intrahepatic tumor progression, liver failure, and portal hypertension continue to drive adverse outcomes in many patients. Interventional radiology plays a central and expanding role in the multidisciplinary management of these tumors by providing image-guided locoregional therapies for local tumor control, downstaging, bridging transplantation or resection, palliation, and potential survival benefit. This narrative review summarizes current evidence and technical considerations for major locoregional approaches, including radiofrequency ablation, microwave ablation, cryoablation, transarterial chemoembolization, transarterial radioembolization, endobiliary therapies, stereotactic body radiation therapy, irreversible electroporation, histotripsy, high-intensity focused ultrasound, hepatic arterial infusion, and brachytherapy. Interventional radiology also contributes to preoperative liver optimization through portal vein embolization, liver venous deprivation, lobar radioembolization to induce contralateral hypertrophy, and, in some patients, portal decompression before hepatic resection. For hepatocellular carcinoma, ablation and transarterial therapies are integrated into stage-based treatment algorithms and may provide curative-intent treatment in some patients. In intrahepatic cholangiocarcinoma, locoregional therapies provide meaningful disease control and may prolong survival, particularly when combined with systemic therapy. In combined hepatocellular cholangiocarcinoma, treatment remains individualized because of limited prospective data and heterogeneous tumor biology. Beyond cytoreduction, locoregional therapies can modulate the tumor immune microenvironment through immunogenic cell death, antigen release, cytokine signaling, and vascular remodeling, providing a rationale for combination strategies with immune checkpoint inhibitors, anti-angiogenic agents, and targeted therapies. As treatment paradigms evolve, the future of interventional radiology in primary liver cancer will depend on appropriate patient selection, optimized dosimetry and technique, integration with molecular and immunologic biomarkers, and coordinated multidisciplinary care.<\/jats:p>","DOI":"10.3390\/cancers18142283","type":"journal-article","created":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T06:49:36Z","timestamp":1784184576000},"page":"2283","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Interventional Radiology in the Management of Primary Liver Malignancies"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3050-4659","authenticated-orcid":false,"given":"Kausthubh","family":"Hegde","sequence":"first","affiliation":[{"name":"Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9232-4069","authenticated-orcid":false,"given":"Ronald","family":"Arellano","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shams","family":"Iqbal","sequence":"additional","affiliation":[{"name":"Division of Interventional Radiology, Department of Radiology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,7,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"107327481772924","DOI":"10.1177\/1073274817729245","article-title":"Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma","volume":"24","author":"Massarweh","year":"2017","journal-title":"Cancer Control"},{"key":"ref_2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Auer, T.A., Collettini, F., Segger, L., Pelzer, U., Mohr, R., Krenzien, F., Gebauer, B., Geisel, D., Hosse, C., and Sch\u00f6ning, W. (2023). Interventional Treatment Strategies in Intrahepatic Cholangiocarcinoma and Perspectives for Combined Hepatocellular-Cholangiocarcinoma. Cancers, 15.","DOI":"10.3390\/cancers15092655"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"100174","DOI":"10.1016\/j.jhepr.2020.100174","article-title":"New insights into the pathophysiology and clinical care of rare primary liver cancers","volume":"3","author":"Gigante","year":"2021","journal-title":"JHEP Rep."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1053\/j.gastro.2019.02.049","article-title":"Surveillance for Hepatocellular Carcinoma: Current Best Practice and Future Direction","volume":"157","author":"Kanwal","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.cld.2020.07.012","article-title":"Tyrosine Kinase Inhibitors and Hepatocellular Carcinoma","volume":"24","author":"Reig","year":"2020","journal-title":"Clin. Liver Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"299","DOI":"10.2217\/imt.15.126","article-title":"Rationally Combining Anti-VEGF Therapy with Checkpoint Inhibitors in Hepatocellular Carcinoma","volume":"8","author":"Hato","year":"2016","journal-title":"Immunotherapy"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Hao, L., Li, S., Deng, J., Li, N., Yu, F., Jiang, Z., Zhang, J., Shi, X., and Hu, X. (2023). The current status and future of PD-L1 in liver cancer. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1323581"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.esmogo.2023.08.004","article-title":"Immune checkpoint inhibition (ICI) in current systemic therapies for hepatocellular carcinoma (HCC)","volume":"1","author":"Berg","year":"2023","journal-title":"ESMO Gastrointest. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Biondetti, P., Saggiante, L., Ierardi, A.M., Iavarone, M., Sangiovanni, A., Pesapane, F., Fumarola, E.M., Lampertico, P., and Carrafiello, G. (2021). Interventional Radiology Image-Guided Locoregional Therapies (LRTs) and Immunotherapy for the Treatment of HCC. Cancers, 13.","DOI":"10.3390\/cancers13225797"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s40364-024-00628-3","article-title":"Abscopal effect: From a rare phenomenon to a new frontier in cancer therapy","volume":"12","author":"Wang","year":"2024","journal-title":"Biomark. Res."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1002\/hep.29913","article-title":"Diagnosis, Staging, and Management of Hepatocellular Carcinoma: 2018 Practice Guidance by the American Association for the Study of Liver Diseases","volume":"68","author":"Marrero","year":"2018","journal-title":"Hepatology"},{"key":"ref_13","unstructured":"European Association for the Study of the Liver (2025). EASL Clinical Practice Guidelines on the management of hepatocellular carcinoma. J. Hepatol., 82, 315\u2013374."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.annonc.2025.02.006","article-title":"Hepatocellular carcinoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"36","author":"Vogel","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"252","DOI":"10.3350\/cmh.2023.0099","article-title":"Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison","volume":"29","author":"Cho","year":"2023","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jhep.2021.11.018","article-title":"BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update","volume":"76","author":"Reig","year":"2022","journal-title":"J. Hepatol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1097\/00000421-198212000-00014","article-title":"Toxicity and response criteria of the Eastern Cooperative Oncology Group","volume":"5","author":"Oken","year":"1982","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1016\/j.rcl.2015.05.012","article-title":"Liver Ablation","volume":"53","author":"Wells","year":"2015","journal-title":"Radiol. Clin. N. Am."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1102\/1470-7330.2009.9026","article-title":"Tumour ablation: Technical aspects","volume":"9","author":"Widmann","year":"2009","journal-title":"Cancer Imaging"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"104685","DOI":"10.4061\/2011\/104685","article-title":"Radiofrequency Ablation of Hepatocellular Carcinoma: A Literature Review","volume":"2011","author":"Minami","year":"2011","journal-title":"Int. J. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1148\/radiol.2021200153","article-title":"The 10-year Survival Analysis of Radiofrequency Ablation for Solitary Hepatocellular Carcinoma 5 cm or Smaller: Primary versus Recurrent HCC","volume":"300","author":"Bai","year":"2021","journal-title":"Radiology"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"106793","DOI":"10.1016\/j.crad.2024.106793","article-title":"Ultrasound-guided intraoperative liver ablation\u2014Retrospective review of indications and outcomes","volume":"82","author":"Rouhezamin","year":"2025","journal-title":"Clin. Radiol."},{"key":"ref_23","doi-asserted-by":"crossref","unstructured":"Hur, M.H., Lee, J.-H., Kim, J.Y., Hong, J.H., Park, M.K., Cho, H.J., Choi, N.R., Kim, J., Kim, M.A., and Nam, J.Y. (2021). Comparison of Overall Survival between Surgical Resection and Radiofrequency Ablation for Hepatitis B-Related Hepatocellular Carcinoma. Cancers, 13.","DOI":"10.3390\/cancers13236009"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1067\/j.cpradiol.2007.08.011","article-title":"Microwave ablation technology: What every user should know","volume":"38","author":"Brace","year":"2009","journal-title":"Curr. Probl. Diagn. Radiol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1916","DOI":"10.1007\/s11547-024-01927-3","article-title":"Percutaneous microwave ablation of HCC: Comparison between 100 and 150 W technology systems","volume":"129","author":"Lanza","year":"2024","journal-title":"Radiol. Med."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Fu, Y., Zhu, Q., Zhao, X., Lu, J., and Wang, W. (2025). Efficacy and safety of ultrasound-guided percutaneous microwave ablation for hepatocellular carcinoma at specific anatomic sites of the liver: A systematic review and meta-analysis. BMC Gastroenterol., 25.","DOI":"10.1186\/s12876-025-04081-w"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S187","DOI":"10.1016\/j.jvir.2009.12.403","article-title":"Cryoablation: Mechanism of action and devices","volume":"21","author":"Erinjeri","year":"2010","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.21037\/qims.2019.11.12","article-title":"Percutaneous cryoablation for the treatment of liver cancer at special sites: An assessment of efficacy and safety","volume":"9","author":"Ma","year":"2019","journal-title":"Quant. Imaging Med. Surg."},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Rong, G., Bai, W., Dong, Z., Wang, C., Lu, Y., Zeng, Z., Qu, J., Lou, M., Wang, H., and Gao, X. (2015). Long-Term Outcomes of Percutaneous Cryoablation for Patients with Hepatocellular Carcinoma within Milan Criteria. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0123065"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1007\/s00270-024-03869-9","article-title":"Percutaneous Cryoablation in the Liver: A Meta-Analysis and Review of Safety with a Focus on Incidence of Cryoshock and Major Complications","volume":"47","author":"Kolck","year":"2024","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1579","DOI":"10.1002\/hep.27548","article-title":"Multicenter randomized controlled trial of percutaneous cryoablation versus radiofrequency ablation in hepatocellular carcinoma","volume":"61","author":"Wang","year":"2015","journal-title":"Hepatology"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Kotsifa, E., Vergadis, C., Vailas, M., Machairas, N., Kykalos, S., Damaskos, C., Garmpis, N., Lianos, G.D., and Schizas, D. (2022). Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?. J. Pers. Med., 12.","DOI":"10.3390\/jpm12030436"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"241","DOI":"10.17998\/jlc.2023.05.22","article-title":"Transarterial chemoembolization for hepatocellular carcinoma: 2023 expert consensus-based practical recommendations of the Korean Liver Cancer Association","volume":"23","author":"Cho","year":"2023","journal-title":"J. Liver Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Lanza, C., Ascenti, V., Amato, G.V., Pellegrino, G., Triggiani, S., Tintori, J., Intrieri, C., Angileri, S.A., Biondetti, P., and Carriero, S. (2025). All You Need to Know About TACE: A Comprehensive Review of Indications, Techniques, Efficacy, Limits, and Technical Advancement. J. Clin. Med., 14.","DOI":"10.3390\/jcm14020314"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3350\/cmh.2019.0021n","article-title":"Switching to systemic therapy after locoregional treatment failure: Definition and best timing","volume":"26","author":"Ogasawara","year":"2020","journal-title":"Clin. Mol. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.1016\/S0140-6736(02)08649-X","article-title":"Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial","volume":"359","author":"Llovet","year":"2002","journal-title":"Lancet"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1053\/jhep.2003.50047","article-title":"Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival","volume":"37","author":"Llovet","year":"2003","journal-title":"Hepatology"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"399","DOI":"10.2217\/hep.15.32","article-title":"Intermediate hepatocellular carcinoma: The role of transarterial therapy","volume":"2","author":"Chegai","year":"2015","journal-title":"Hepatic Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1758835920970840","DOI":"10.1177\/1758835920970840","article-title":"Management of patients with intermediate stage hepatocellular carcinoma","volume":"12","author":"Prince","year":"2020","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s12325-016-0324-7","article-title":"Transarterial Radioembolization with Yttrium-90 for the Treatment of Hepatocellular Carcinoma","volume":"33","author":"Kallini","year":"2016","journal-title":"Adv. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/j.jvir.2020.12.019","article-title":"Pathologic Response of Hepatocellular Carcinoma Treated with Yttrium-90 Glass Microsphere Radiation Segmentectomy Prior to Liver Transplantation: A Validation Study","volume":"32","author":"Toskich","year":"2021","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/s00259-020-04976-8","article-title":"Correlation of Y90-absorbed radiation dose to pathological necrosis in hepatocellular carcinoma: Confirmatory multicenter analysis in 45 explants","volume":"48","author":"Gabr","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1053\/j.gastro.2016.08.029","article-title":"Y90 Radioembolization Significantly Prolongs Time to Progression Compared with Chemoembolization in Patients with Hepatocellular Carcinoma","volume":"151","author":"Salem","year":"2016","journal-title":"Gastroenterology"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/hep.31819","article-title":"Yttrium-90 Radioembolization for the Treatment of Solitary, Unresectable HCC: The LEGACY Study","volume":"74","author":"Salem","year":"2021","journal-title":"Hepatology"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2898","DOI":"10.21873\/invivo.14090","article-title":"Relationship Between Dose and Local Control in Five-fraction Stereotactic Body Radiotherapy for Hepatocellular Carcinoma","volume":"39","author":"Nishikawa","year":"2025","journal-title":"In Vivo"},{"key":"ref_46","doi-asserted-by":"crossref","unstructured":"Hatzidakis, A., M\u00fcller, L., Krokidis, M., and Kloeckner, R. (2022). Local and Regional Therapies for Hepatocellular Carcinoma and Future Combinations. Cancers, 14.","DOI":"10.3390\/cancers14102469"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JHC.S129063","article-title":"Irreversible electroporation of hepatocellular carcinoma: Patient selection and perspectives","volume":"4","author":"Zimmerman","year":"2017","journal-title":"J. Hepatocell. Carcinoma"},{"key":"ref_48","unstructured":"(2026, June 25). Device Classification Under Section 513(f)(2)(De Novo) [Internet], Available online: https:\/\/www.accessdata.fda.gov\/scripts\/cdrh\/cfdocs\/cfpmn\/denovo.cfm?id=DEN220087."},{"key":"ref_49","first-page":"7227","article-title":"First FDA approved experience with histotripsy for liver cancer management","volume":"112","author":"Byrne","year":"2025","journal-title":"Int. J. Surg."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Queen, H., Ferris, S.F., Cho, C.S., and Ganguly, A. (2025). The Emerging Role of Histotripsy in Liver Cancer Treatment: A Scoping Review. Cancers, 17.","DOI":"10.3390\/cancers17060915"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.cgh.2012.09.009","article-title":"Classification, Diagnosis, and Management of Cholangiocarcinoma","volume":"11","author":"Razumilava","year":"2013","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Owen, M., Makary, M.S., and Beal, E.W. (2023). Locoregional Therapy for Intrahepatic Cholangiocarcinoma. Cancers, 15.","DOI":"10.3390\/cancers15082384"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Bekki, Y., Von Ahrens, D., Takahashi, H., Schwartz, M., and Gunasekaran, G. (2021). Recurrent Intrahepatic Cholangiocarcinoma\u2014Review. Front. Oncol., 11.","DOI":"10.3389\/fonc.2021.776863"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/S1470-2045(21)00027-9","article-title":"Second-line FOLFOX chemotherapy versus active symptom control for advanced biliary tract cancer (ABC-06): A phase 3, open-label, randomised, controlled trial","volume":"22","author":"Lamarca","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"EVIDoa2200015","DOI":"10.1056\/EVIDoa2200015","article-title":"Durvalumab plus gemcitabine and cisplatin in advanced biliary tract cancer","volume":"1","author":"Oh","year":"2022","journal-title":"NEJM Evid."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"115432","DOI":"10.1016\/j.ejca.2025.115432","article-title":"Real-world efficacy of zanidatamab in patients with HER2 positive advanced biliary tract cancers","volume":"222","author":"Smolenschi","year":"2025","journal-title":"Eur. J. Cancer"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s00330-021-08216-x","article-title":"Thermal ablation in the treatment of intrahepatic cholangiocarcinoma: A systematic review and meta-analysis","volume":"32","author":"Kim","year":"2022","journal-title":"Eur. Radiol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-0039-1696649","article-title":"Ablation of Intrahepatic Cholangiocarcinoma","volume":"36","author":"Sweeney","year":"2019","journal-title":"Semin. Interv. Radiol."},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Braunwarth, E., Schullian, P., Kummann, M., Reider, S., Putzer, D., Primavesi, F., St\u00e4ttner, S., \u00d6fner, D., and Bale, R. (2022). Aggressive local treatment for recurrent intrahepatic cholangiocarcinoma\u2014Stereotactic radiofrequency ablation as a valuable addition to hepatic resection. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0261136"},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Xiang, X., Hu, D., Jin, Z., Liu, P., and Lin, H. (2020). Radiofrequency Ablation vs. Surgical Resection for Small Early-Stage Primary Intrahepatic Cholangiocarcinoma. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.540662"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1080\/02656736.2019.1571247","article-title":"Ultrasound-guided percutaneous microwave ablation versus surgical resection for recurrent intrahepatic cholangiocarcinoma: Intermediate-term results","volume":"36","author":"Xu","year":"2019","journal-title":"Int. J. Hyperth."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Briot, A., Br\u00e9hier, G., Jaillais, A., David, A., Girot, P., Reboux, N., Boil\u00e8ve, A., and Touchefeu, Y. (2024). Efficacy of Monopolar Radiofrequency or Microwave Ablation in Intrahepatic Cholangiocarcinoma: A Retrospective Multicenter Study from Association des Gastro-Ent\u00e9rologues Oncologues (AGEO). Cancers, 16.","DOI":"10.3390\/cancers16223838"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1007\/s00432-022-04485-1","article-title":"Conventional and drug-eluting beads transarterial chemoembolization in patients with unresectable intrahepatic cholangiocarcinoma: A systematic review and pooled analysis","volume":"149","author":"He","year":"2023","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1007\/s00270-021-02800-w","article-title":"Transarterial Chemoembolization and Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma-a Systemic Review and Meta-Analysis","volume":"44","author":"Mosconi","year":"2021","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_66","first-page":"6584","article-title":"Comparison of the efficacy and safety among apatinib plus drug-eluting bead transarterial chemoembolization (TACE), apatinib plus conventional TACE and apatinib alone in advanced intrahepatic cholangiocarcinoma","volume":"12","author":"Hu","year":"2020","journal-title":"Am. J. Transl. Res."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.jvir.2022.02.016","article-title":"Transarterial Yttrium-90 Radioembolization for Unresectable Intrahepatic Cholangiocarcinoma: A Systematic Review and Meta-Analysis","volume":"33","author":"Schartz","year":"2022","journal-title":"J. Vasc. Interv. Radiol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1007\/s00270-020-02569-4","article-title":"Yttrium-90 Radioembolization in Unresectable Intrahepatic Cholangiocarcinoma: Results of a Multicenter Retrospective Study","volume":"43","author":"Bargellini","year":"2020","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1245\/s10434-019-08142-9","article-title":"Hypofractionated Radiation Therapy for Unresectable\/Locally Recurrent Intrahepatic Cholangiocarcinoma","volume":"27","author":"Smart","year":"2020","journal-title":"Ann. Surg. Oncol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1200\/JCO.2015.61.3778","article-title":"Ablative Radiotherapy Doses Lead to a Substantial Prolongation of Survival in Patients with Inoperable Intrahepatic Cholangiocarcinoma: A Retrospective Dose Response Analysis","volume":"34","author":"Tao","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1001\/jamaoncol.2019.3718","article-title":"Assessment of Hepatic Arterial Infusion of Floxuridine in Combination with Systemic Gemcitabine and Oxaliplatin in Patients with Unresectable Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"Cercek","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1007\/s00270-011-0249-0","article-title":"Computed tomography-guided interstitial HDR brachytherapy (CT-HDRBT) of the liver in patients with irresectable intrahepatic cholangiocarcinoma","volume":"35","author":"Schnapauff","year":"2012","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Iqbal, S., Hegde, K., Arellano, R., Uppot, R., Zhao, S., An, T., Ellis, H., and Weissleder, R. (2026). Percutaneous Endobiliary Radiofrequency Ablation (PERFA) for Unresectable Cholangiocarcinoma. Acad. Radiol.","DOI":"10.1016\/j.acra.2026.02.034"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"E23","DOI":"10.1055\/a-2204-8316","article-title":"Intraductal radiofrequency ablation plus biliary stent versus stent alone for malignant biliary obstruction: A systematic review and meta-analysis","volume":"12","author":"Veras","year":"2024","journal-title":"Endosc. Int. Open."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/jamaoncol.2019.3702","article-title":"Radioembolization Plus Chemotherapy for First-line Treatment of Locally Advanced Intrahepatic Cholangiocarcinoma: A Phase 2 Clinical Trial","volume":"6","author":"Edeline","year":"2020","journal-title":"JAMA Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Choi, J.H., and Ro, J.Y. (2022). Combined Hepatocellular-Cholangiocarcinoma: An Update on Pathology and Diagnostic Approach. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081826"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Na, S.K., Choi, G.H., Lee, H.C., Shin, Y.M., An, J., Lee, D., Shim, J.H., Kim, K.M., Lim, Y.-S., and Chung, Y.-H. (2018). The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0198138"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1007\/s00270-017-1648-7","article-title":"Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma","volume":"40","author":"Chan","year":"2017","journal-title":"Cardiovasc Interv. Radiol."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1159\/000508386","article-title":"Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma","volume":"7","author":"Badar","year":"2020","journal-title":"Gastrointest. Tumors"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00270-024-03743-8","article-title":"CIRSE Standards of Practice on Portal Vein Embolization and Double Vein Embolization\/Liver Venous Deprivation","volume":"47","author":"Bilhim","year":"2024","journal-title":"Cardiovasc. Interv. Radiol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00330-017-4744-9","article-title":"Extended liver venous deprivation before major hepatectomy induces marked and very rapid increase in future liver remnant function","volume":"27","author":"Guiu","year":"2017","journal-title":"Eur. Radiol."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Chaouch, M.A., Mazzotta, A., da Costa, A.C., Hussain, M.I., Gouader, A., Krimi, B., Panaro, F., Guiu, B., Soubrane, O., and Oweira, H. (2024). A systematic review and meta-analysis of liver venous deprivation versus portal vein embolization before hepatectomy: Future liver volume, postoperative outcomes, and oncological safety. Front. Med., 10.","DOI":"10.3389\/fmed.2023.1334661"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jhep.2013.06.015","article-title":"Radiation lobectomy: Time-dependent analysis of future liver remnant volume in unresectable liver cancer as a bridge to resection","volume":"59","author":"Vouche","year":"2013","journal-title":"J. Hepatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1002\/jso.24269","article-title":"90Y radiation lobectomy: Outcomes following surgical resection in patients with hepatic tumors and small future liver remnant volumes","volume":"114","author":"Lewandowski","year":"2016","journal-title":"J. Surg. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"110842","DOI":"10.1016\/j.clinimag.2026.110842","article-title":"Portosystemic shunt creation in hepatic malignancies: Evaluation of risk for pulmonary metastasis development and progression","volume":"136","author":"Hegde","year":"2026","journal-title":"Clin. Imaging"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Balducci, D., Montori, M., De Blasio, F., Di Bucchianico, A., Argenziano, M.E., Baroni, G.S., and Scarpellini, E. (2023). The Role of Transjugular Intrahepatic Portosystemic Shunt (TIPS) in Treating Portal Hypertension in Patients with Hepatocellular Carcinoma. Medicina, 59.","DOI":"10.3390\/medicina59061150"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"100442","DOI":"10.1016\/j.jhepr.2022.100442","article-title":"Preoperative TIPS prevents the development of postoperative acute-on-chronic liver failure in patients with high CLIF-C AD score","volume":"4","author":"Chang","year":"2022","journal-title":"JHEP Rep."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1148\/radiol.2511072175","article-title":"Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity","volume":"251","author":"Dromi","year":"2009","journal-title":"Radiology"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1002\/hep.26153","article-title":"Enhancement of tumor-associated antigen-specific T cell responses by radiofrequency ablation of hepatocellular carcinoma","volume":"57","author":"Mizukoshi","year":"2013","journal-title":"Hepatology"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1053\/j.gastro.2009.12.051","article-title":"Radiofrequency thermal ablation for hepatocellular carcinoma stimulates autologous NK-cell response","volume":"138","author":"Zerbini","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1080\/0265673021000017154","article-title":"Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma","volume":"19","author":"Dong","year":"2003","journal-title":"Int. J. Hyperth."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1007\/s00262-020-02734-1","article-title":"Microwave ablation enhances tumor-specific immune response in patients with hepatocellular carcinoma","volume":"70","author":"Leuchte","year":"2021","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"450","DOI":"10.4161\/cbt.11.5.14669","article-title":"Phase I clinical study of combination therapy with microwave ablation and cellular immunotherapy in hepatocellular carcinoma","volume":"11","author":"Zhou","year":"2011","journal-title":"Cancer Biol. Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/13645706.2017.1286356","article-title":"Effects of microwave ablation on T-cell subsets and cytokines of patients with hepatocellular carcinoma","volume":"26","author":"Zhang","year":"2017","journal-title":"Minim. Invasive Ther. Allied Technol."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Zeng, Z., Shi, F., Zhou, L., Zhang, M.-N., Chen, Y., Chang, X.-J., Lu, Y.-Y., Bai, W.-L., Qu, J.-H., and Wang, C.-P. (2011). Upregulation of circulating PD-L1\/PD-1 is associated with poor post-cryoablation prognosis in patients with HBV-related hepatocellular carcinoma. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0023621"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"3473","DOI":"10.3748\/wjg.v19.i22.3473","article-title":"Combination treatment with comprehensive cryoablation and immunotherapy in metastatic hepatocellular cancer","volume":"19","author":"Niu","year":"2013","journal-title":"World J. Gastroenterol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"81967","DOI":"10.18632\/oncotarget.17804","article-title":"Cryoablation combined with allogenic natural killer cell immunotherapy improves the curative effect in patients with advanced hepatocellular cancer","volume":"8","author":"Lin","year":"2017","journal-title":"Oncotarget"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Guo, X., Du, F., Liu, Q., Guo, Y., Wang, Q., Huang, W., Wang, Z., Ding, X., and Wu, Z. (2021). Immunological effect of irreversible electroporation on hepatocellular carcinoma. BMC Cancer, 21.","DOI":"10.1186\/s12885-021-08176-x"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s12072-020-10014-4","article-title":"Effects of transarterial chemoembolization on regulatory T cell and its subpopulations in patients with hepatocellular carcinoma","volume":"14","author":"Park","year":"2020","journal-title":"Hepatol. Int."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1007\/s13277-012-0504-2","article-title":"Predictive value of immunogenic cell death biomarkers HMGB1, sRAGE, and DNase in liver cancer patients receiving transarterial chemoembolization therapy","volume":"33","author":"Kohles","year":"2012","journal-title":"Tumour Biol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.cyto.2013.07.021","article-title":"Change in inflammatory cytokine profiles after transarterial chemotherapy in patients with hepatocellular carcinoma","volume":"64","author":"Kim","year":"2013","journal-title":"Cytokine"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1136\/gutjnl-2017-315485","article-title":"Immune activation underlies a sustained clinical response to Yttrium-90 radioembolisation in hepatocellular carcinoma","volume":"68","author":"Chew","year":"2019","journal-title":"Gut"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s00262-018-2141-0","article-title":"Impaired lymphocyte function in patients with hepatic malignancies after selective internal radiotherapy","volume":"67","author":"Domouchtsidou","year":"2018","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1111\/liv.12592","article-title":"Radioembolization of hepatocellular carcinoma activates liver regeneration, induces inflammation and endothelial stress and activates coagulation","volume":"35","author":"Paramo","year":"2015","journal-title":"Liver Int."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/S2468-1253(21)00305-8","article-title":"Radioembolisation with Y90-resin microspheres followed by nivolumab for advanced hepatocellular carcinoma (CA 209\u2013678): A single arm, single centre, phase 2 trial","volume":"6","author":"Tai","year":"2021","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1158\/1078-0432.CCR-21-1219","article-title":"Immune Profiling of Combined Hepatocellular-Cholangiocarcinoma Reveals Distinct Subtypes and Activation of Gene Signatures Predictive of Response to Immunotherapy","volume":"28","author":"Nguyen","year":"2022","journal-title":"Clin. Cancer Res."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2283\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,16]],"date-time":"2026-07-16T07:07:18Z","timestamp":1784185638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/14\/2283"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,16]]},"references-count":106,"journal-issue":{"issue":"14","published-online":{"date-parts":[[2026,7]]}},"alternative-id":["cancers18142283"],"URL":"https:\/\/doi.org\/10.3390\/cancers18142283","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,16]]}}}